The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Subcutaneous
Route
3 recommended
Sites
Once daily
Frequency
Preparation
Bacteriostatic water (BAC water)
Insulin syringes (29-31 gauge)
Alcohol swabs
Sharps container
Pro tip
Prepare all supplies on a clean surface before you begin. Having everything ready makes the process smoother and more sterile.
Mixing
Wash your hands thoroughly with soap and water. Gather all supplies on a clean, flat surface.
Remove the plastic cap from the peptide vial and wipe the rubber stopper with an alcohol swab. Let it air dry.
Draw the appropriate amount of bacteriostatic water into a sterile syringe.
Insert the needle into the vial at an angle, aiming at the inside wall of the vial. Slowly push the plunger to let the water trickle down the glass wall -- do NOT squirt directly onto the powder.
Once all water is added, gently swirl the vial in a slow circular motion. Never shake the vial, as this can damage the peptide bonds.
Continue swirling until the powder is completely dissolved and the solution is clear. If particles remain, let the vial sit for a few minutes and swirl again.
Label the vial with the date of reconstitution, the peptide name, and the concentration (e.g. 250mcg per 0.1mL).
Example calculation
If using a standard vial, add bacteriostatic water to achieve your desired concentration. For example, adding 2mL of BAC water to a vial allows precise dosing with an insulin syringe.
Dose calculation
Draw up the appropriate volume based on your reconstitution ratio. Consult dosing charts for exact volumes corresponding to 250-500 mcg doses.
Pro tip
Always add the bacteriostatic water slowly, letting it run down the side of the vial. Never shake the vial -- swirl gently to avoid damaging the peptide.
Location
Site 01
Abdomen
Pinch the skin 2 inches from navel. Avoid the area directly around the belly button. Rotate between left and right sides.
Site 02
Outer Thigh
Middle third of the outer thigh. Keep at least 4 inches above the knee and below the hip. Alternate legs each injection.
Site 03
Upper Arm
Back or outer area of the upper arm. This site may require assistance from another person for proper technique.
Rotate between 3 sites to prevent tissue buildup and ensure consistent absorption.
Pro tip
Rotate your injection sites with each dose to prevent lipohypertrophy (buildup of fatty tissue). Keep a simple log of where you last injected.
Step by step
Wash hands and prepare clean workspace
Clean injection site with alcohol swab
Draw correct dose into insulin syringe
Pinch skin and insert needle at 45-90 degree angle
Inject slowly, withdraw needle
Apply gentle pressure—do not rub
Dispose of syringe in sharps container
Pro tip
This peptide uses subcutaneous injection (into the fatty tissue just under the skin). Inject at a 45-90 degree angle into pinched skin. Aspirate before injecting to ensure you haven't hit a blood vessel.
Timing
Optimal timing
Best time
Administer at a consistent time each day. Consistency matters more than the specific time of day.
With food?
Food timing does not significantly affect absorption for injectable peptides.
Stacking notes
If combining BPC-157 with other peptides, space administrations by 15-30 minutes. Consult your healthcare provider before combining with prescription medications.
Sample daily schedule
Morning (8:00 AM)
250mcg injection
Site: Near injury or abdomen
Administer via subcutaneous injection in the morning for consistency. Inject near the site of injury for optimal localized healing effects, or in the abdomen for systemic benefits.
Evening (8:00 PM)
250mcg injection
Site: Rotate from morning
Duration: Continue for 4-6 weeks. Then: 2-4 week break before restarting if needed.
Dosing tiers
Dose
250 mcg
Frequency
Once daily
Duration
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
Preservation
Before mixing
Store in refrigerator at 36-46°F (2-8°C). Keep in original packaging to protect from light. Do not freeze.
After mixing
Store reconstituted solution in refrigerator at 36-46°F (2-8°C). Use within 30 days. Do not freeze reconstituted solution.
Shelf life after mixing
30 days
Signs of degradation
Discard the vial immediately if you notice any of these:
Solution appears cloudy or discolored
Visible particles or precipitates in solution
Solution has changed color from original appearance
Vial has been exposed to temperatures above 77°F (25°C) for extended periods
Important
When to stop
If you experience severe or persistent injection site reactions or signs of infection
If you develop signs of an allergic reaction such as difficulty breathing, swelling, or severe rash
If healing progress plateaus after 6+ weeks of continuous use, indicating need for reassessment or alternative approaches
Always consult with a healthcare provider before discontinuing BPC-157, especially if used for active injury recovery. Do not stop abruptly without medical guidance as this may impact healing outcomes.
Clean technique checklist
Wash hands thoroughly with soap and water before handling supplies
Swab vial tops and injection site with alcohol and let dry
Never touch the needle tip or allow it to contact non-sterile surfaces
Use a new syringe and needle for each injection
Dispose of used sharps in a proper sharps container
Store reconstituted peptides according to the storage instructions above
Published research
Sikiric et al. · 2018
Demonstrated healing across multiple tissue types including tendon, ligament, muscle, and gut lining with no observed toxicity.
Seiwerth S, Milavic M, Vukojevic J, et al. · 2021
Accelerated wound closure and tissue regeneration in multiple animal models.
Chang et al. · 2011
Significantly improved tendon-to-bone healing in rat rotator cuff model.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P · 2025
Open-access review (Pharmaceuticals 2025). BPC 157 has not been approved for use in standard medicine by the FDA or other regulators owing to the absence of sufficient and comprehensive clinical studies in humans. Most, if not all, studies are limited to small animal models (rats and mice); human studies are scarce — a retrospective 12-patient knee-pain study and a Phase I trial in 42 healthy volunteers started in 2015, for which submission of results was cancelled in 2016. No toxic dose has been determined in rat and dog toxicity studies. The review calls for in-depth analysis of the mechanism of action, describing it as still unknown.
Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. · 2026
Open-access narrative review (Pharmaceutics 2026). BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II trial; early-phase Pliva investigations in inflammatory bowel disease (PL-10, PLD-116, PL14736) were not followed by Phase II or III trials, and available clinical data come from fewer than 30 subjects across three uncontrolled pilot studies. It was derived from a protein fragment in human gastric juice, and the GI tract is its most extensively characterised domain. It acts through multiple overlapping signalling pathways — documented targets include VEGFR2, Egr-1, the NO system and growth hormone receptor signalling — though no high-affinity receptor binding site has been identified and its molecular target remains formally unknown. Parenteral administration is described as the most pharmacokinetically reliable route; oral effects in rodents may reflect local mucosal action.
Vasireddi N, Hahamyan H, Salata MJ, et al. · 2025
Systematic review (HSS Journal 2025) of 36 studies (35 preclinical, 1 clinical). BPC-157 lacks US FDA approval and is banned in professional sports. In preclinical models it improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries; preclinical safety studies showed no adverse effects, and no clinical safety data were found. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.
Yuan C, Demers A, Silva-Ortiz V, et al. · 2026
Open-access review (Int J Mol Sci 2026). Preclinical evidence shows BPC-157 supports angiogenesis, collagen synthesis and fibroblast activity, enhancing healing of muscle, tendon, ligament, bone and GI tissue. Human research is limited to small pilot studies. BPC-157 does not have FDA approval; complaints from unregulated use may reflect unregulated production and variable dosing, and standardisation and regulation of its preparation is described as necessary to prevent contamination.
Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S · 2009
In rat crushed-muscle and transected muscle and tendon models, immunohistochemistry (VEGF, CD34, FVIII) showed adequately modulated angiogenesis in BPC 157-treated animals; the authors conclude BPC 157 stimulates angiogenesis by up-regulating VEGF expression, with no direct angiogenic effect on cell cultures.
Sikiric P, Seiwerth S, Grabarevic Z, et al. · 1997
In rat adjuvant arthritis (14 days to 1 year), BPC 157 (10 µg or 10 ng/kg i.p.) reduced lesion development and, given as therapy for established arthritis, produced a salutary effect after 2 weeks that persisted at 1 year; the authors conclude the data point to a special anti-inflammatory and mucosal-integrity protective effect.
Lee E, Padgett B · 2021
Retrospective chart review of 16 patients: 11 of 12 given intra-articular BPC 157 alone reported significant improvement in knee pain (14 of 16 overall including BPC 157 + TB4). No standardised outcome tools were used. The authors describe BPC 157 as a peptide with regenerative properties with the potential to repair tears and build cartilage.
Park JM, Lee HJ, Sikiric P, Hahm KB · 2020
Review (Curr Pharm Des 2020) describing, for the first time, the potential rescuing actions of BPC 157 against leaky gut syndrome after NSAID administration, via stabilised intestinal permeability and cytoprotection.
Matek D, Matek I, Japjec M, et al. · 2026
Open-access review (Pharmaceuticals 2026). Without any carrier, BPC 157 given systemically or locally combined beneficial effects on tendon, ligament and muscle injuries and junctional healing; in rat studies, across systemic (intraperitoneal, intragastric, drinking water) and local (cream) administration, it consistently demonstrated efficacy.